u266 b1 human multiple myeloma b lymphocyte cell line  (ATCC)

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Identification of constructed TCF4−/+ U266 and MMSA−1−/+ U266 stable cell lines and MMSA-1 mRNA and protein levels in TCF4−/+ U266 cells 1: U266 cells; 2: TCF4− U266-NC; 3. TCF4− U266 cells; 4: TCF4+ U266-NC; 5. TCF4+ U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Construct, Stable Transfection

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Dual-Luciferase Report Assay results in different U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Luciferase

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: MMSA-1 and RAS co-localization and interaction in U266 cells 1: U266 cells; 2: MMSA−1− U266-NC; 3. MMSA−1− U266 cells; 4: MMSA−1+ U266-NC; 5. MMSA−1+ U266 cells

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques:

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: RAS downstream related molecule expressions in different U266 cells 1: U266; 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4: MMSA−1+ U266-NC; 5. MMSA−1 + U266

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques:

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: MMSA-1’s effect on U266 cells proliferation, migration and apoptosis A showed cloning formation assay result; B showed transwell assay result; C showed apoptosis related proteins expression and D showed mitochondrial apoptosis in different U266 cells. 1: U266; 2: U266 + CCCP-1; 3. MMSA−1− U266-NC; 4. MMSA−1− U266-NC + CCCP-1; 5. MMSA−1− U266; 6: MMSA−1− U266 + CCCP-1; 7. MMSA−1+ U266-NC; 8. MMSA−1+ U266-NC + CCCP-1; 9. MMSA−1 + U266; 10. MMSA−1 + U266 + CCCP-1

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Migration, Cloning, Tube Formation Assay, Transwell Assay, Expressing

Journal: Annals of Hematology

Article Title: MMSA-1 is regulated by Wnt/TCF4 and involved in multiple myeloma progression and invasion via RAS/RAF signaling pathway

doi: 10.1007/s00277-026-06740-8

Figure Lengend Snippet: Adhesion molecules and angiogenesis factors levels in different U266 cells A showed qRT-PCR result and B showed Western Blot result of adhesion molecules; C showed angiogenesis factors levels. 1: U266 cells, 2: MMSA−1− U266-NC; 3. MMSA−1− U266; 4. MMSA−1+ U266-NC; 5. MMSA−1+ U266

Article Snippet: Human multiple myeloma cell line U266 and 293 T were purchased from Wuhan Procell Life Science&Technology Co., Ltd, both of which have been identified by Short Tandem Repeat (STR).

Techniques: Quantitative RT-PCR, Western Blot

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR decreases IgE secretion but not IgG secretion. The expression of IgE by IgE-producing myeloma cells, U266, was determined by ELISA following berberine (BBR) treatment at 10, 5, and 2.5 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) for 6 days ( A ). The expression of IgG by IgG-producing myeloma cells, ARH-77, was determined by ELISA, treated as U266 ( B ). N = 3–4, ** p ≤ 0.01, *** p ≤ 0.0001, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Expressing, Enzyme-linked Immunosorbent Assay, Concentration Assay

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR does not affect the viability of IgE or IgG producing cells. ( A ) The viability of IgE by IgE-producing myeloma cells, U266, was determined by trypan blue exclusion assay, following berberine (BBR) treatment at 10, 5, and 2.5 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) for 6 days. ( B ) The same was performed for IgG-producing myeloma cells, ARH-77. ( C ) Total cell count determined by Trypan Blue was used to determine total cells per mL of U266 cells and ( D ) ARH-77 cells. N = 3. BBR= Berberine. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Trypan Blue Exclusion Assay, Concentration Assay, Cell Counting

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR affects proliferation of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) The proliferation of IgE by IgE-producing myeloma cells, U266, was determined by XTT assay, following berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) for 6 days. ( B ) The same was performed for IgG-producing myeloma cells, ARH-77. N = 3. BBR = berberine, DMSO = dimethyl sulfoxide. * p ≤ 0.05, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: XTT Assay, Concentration Assay

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR affects cell cycle genes of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) qRT-PCR of IgE heavy chain ( IGHE ) and cell cycle genes cyclin D1 ( CCND1 ), tumor protein 53 ( TP53 ), and growth arrest and DNA-damage inducible alpha ( GADD45A ), in IgE-producing U266 were performed after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL). qPCR analysis of cell cycle proteins of IgE-producing U266 was performed after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL) and data were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH) expression. ( B ) The same was performed for ARH-77, with analysis of IgG heavy chain ( IGHG ). N = 3. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Quantitative RT-PCR, Concentration Assay, Expressing

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR affects cell cycle genes of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) Western Blot analysis of cell cycle genes in IgE-producing U266 was performed after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL). ( B ) The same was performed for ARH-77. N = 3. CDK2 = cyclin dependent protein kinase 2, CDKN1C = cyclin dependent kinase inhibitor 1C, TP53 = tumor protein 53. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Western Blot, Concentration Assay

Journal: Cells

Article Title: A Small Molecule Compound, Berberine Reduces IgE but Not IgG Production via Promoting miRNA-34a-p53 Axis

doi: 10.3390/cells14221799

Figure Lengend Snippet: BBR affects expression of miRNAs involved in modulation of the p53 pathway of IgE-producing myeloma cells with no effect on IgG-producing myeloma cells. ( A ) miRNA isolation and qPCR analysis of miRNAs (miR) implicated IgE-regulation, miR-155, miR-143, miR-34a, and miR-146a were performed on U266 after 6 days of berberine (BBR) treatment at 10 μg/mL compared to the equivalent concentration of DMSO (0 μg/mL). ( B ) The same was performed for ARH-77. N = 3. * p ≤ 0.05, ** p ≤ 0.01, ns = not significant. Each dot represents a single biological replicate.

Article Snippet: The IgE-producing human myeloma U266 cell line and IgG-producing human myeloma ARH-77 cell lines were obtained from American Type Culture Collection, (ATCC, Rockville, MD, USA).

Techniques: Expressing, Isolation, Concentration Assay

Journal: Scientific Reports

Article Title: Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy

doi: 10.1038/s41598-025-97584-1

Figure Lengend Snippet: High cytotoxicity of anti-BCMA CAR LRF-NK and PB-NK cells against BCMA-expressing cells. ( A ) Flow cytometric analysis depicts CD107a expression on anti-BCMA CAR LRF-NK cells (GFP + population) post-co-culture with U266-B1 cells (BCMA + cells). ( B ) the mean percentage of CD107a expression on anti-BCMA CAR LRF-NK cells (GFP + population) after co-culture with CCRF-CEM (BCMA − cells) and K562 cell lines. ( C ) Statistical analysis indicates significantly elevated CD107a expression on anti-BCMA CAR LRF- and PB-NK cells when co-cultured with U266-B1 compared to CCRF-CEM and K562 cells. No significant difference in CD107a expression exists between anti-BCMA CAR LRF- and PB-NK cells. Data presented as Mean ± SD. (** Represents P < 0.001, and *** P < 0.0001, N = 3). LRF: Leukocyte reduction filter. PB: peripheral blood.

Article Snippet: The human BCMA + multiple myeloma cell line (U266-B1), BCMA- acute lymphoblastic leukemia cell line (CCRF-CEM), human erythroleukemic cell line (K562), and human embryonic kidney cell line (HEK293T) were procured from the Pasteur Institute (Tehran, Iran).

Techniques: Expressing, Co-Culture Assay, Cell Culture

Journal: Scientific Reports

Article Title: Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy

doi: 10.1038/s41598-025-97584-1

Figure Lengend Snippet: Specific activation of transduced NK cells. ( A ) The baseline expression levels of CD69 (upper left) on anti-BCMA CAR LRF-NK cells, when cultured alone and CD69 expression following the co-cultivation of anti-BCMA CAR LRF-NK cells with U266-B1 (upper right) CCRF-CEM (Lower Left) and K562 (lower left) cell lines. ( B ) The mean percentage of CD69 as an early activation marker significantly increased on anti-BCMA CAR LRF/PB cells following co-cultivation with the U266-B1 compared to CCRF-CEM cell lines.

Article Snippet: The human BCMA + multiple myeloma cell line (U266-B1), BCMA- acute lymphoblastic leukemia cell line (CCRF-CEM), human erythroleukemic cell line (K562), and human embryonic kidney cell line (HEK293T) were procured from the Pasteur Institute (Tehran, Iran).

Techniques: Activation Assay, Expressing, Cell Culture, Marker

Journal: Scientific Reports

Article Title: Leukoreduction filter derived NK cells offer a promising source for off the shelf CAR NK cell immunotherapy

doi: 10.1038/s41598-025-97584-1

Figure Lengend Snippet: mRNA expression of IFN-γ ( A ) and granzyme B ( B ) in anti-BCMA CAR LRF-NK and PB-NK cells following co-culture with U266-B1 (BCMA + ), CCRF-CEM (BCMA − ), and K562 Cell Lines. The augmented expression of IFN-γ and granzyme B was evident in LRF-NK and PB-NK cells after co-cultivation with the K562 cell line, as opposed to their counterparts co-cultivated with U266-B1 and CCRF-CEM cell lines, as well as IL-2 treated NK cells. No statistically significant distinctions were discerned between LRF-NK and PB-NK cells. Conversely, Anti-BCMA CAR NK cells demonstrated a notable increase in the expression of IFN-γ and GrB after co-culture with U266-B1 compared to CCRF-CEM. The absence of significant differences between LRF and PB CAR NK cells in IFN-γ and GrB expression under identical conditions is noteworthy. Notably, a significantly heightened expression of IFN-γ and GrB in CAR NK cells compared to regular NK cells was observed after co-culture with U266-B1 cells. Data are presented as mean ± SD. (Double asterisks (**) signify P < 0.001, and triple asterisks (***) denote P < 0.0001; N = 3). LRF: leukocyte reduction filter. PB: peripheral blood.

Article Snippet: The human BCMA + multiple myeloma cell line (U266-B1), BCMA- acute lymphoblastic leukemia cell line (CCRF-CEM), human erythroleukemic cell line (K562), and human embryonic kidney cell line (HEK293T) were procured from the Pasteur Institute (Tehran, Iran).

Techniques: Expressing, Co-Culture Assay